Sponsor

Jianxing He

Clinical research sponsor

Published trials9
Recruiting shown1
Roles1
SourceClinicalTrials.gov

Clinical trials

9 shown
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLCNCT07492342 · lead sponsor · 2026-01-29
RECRUITING
Single-Center Intelligent Pulmonary Rehabilitation After Lung Cancer SurgeryNCT07631533 · lead sponsor · 2026-06-01
NOT_YET_RECRUITING
Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLCNCT07177105 · lead sponsor · 2025-09-10
NOT_YET_RECRUITING
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung CancerNCT07177092 · lead sponsor · 2025-09-08
NOT_YET_RECRUITING
AI-Based DeepGEM Tool for Predicting Gene Mutations in NSCLC Patients: A Randomized Controlled StudyNCT07110259 · lead sponsor · 2025-07-31
NOT_YET_RECRUITING
Early Feeding and Mobilization in Thoracic SurgeryNCT07232394 · lead sponsor · 2025-01-01
COMPLETED
ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest SurgeryNCT07201077 · lead sponsor · 2025-01-01
COMPLETED
Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After LobectomyNCT05472350 · lead sponsor · 2022-08-01
UNKNOWN
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLCNCT02988141 · lead sponsor · 2017-03-01
UNKNOWN

Sponsor roles

lead sponsor9

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.